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Original Article
Cold Therapy in Migraine Patients: Open-label, Non-controlled,
Pilot Study
Serap Ucler, Ozlem Coskun, Levent E. Inan and Yonca Kanatli
Department of Neurology, Ankara Training and Research Hospital, Ministry of Health, Ankara, Turkey
Some patients with headache report that they have frequently used physical therapies such as application
of cold to relieve their headache. There are only a few reported studies related to cold therapies in
patients with migraine. In this study, we investigated the effect of cold application on migraine patients.
Twenty-eight migraine patients were included. Cold therapy was administered to them by gel cap.
Patients used this cap during their two migraine attacks. Before and after the cold therapy, headache
severity was recorded by using visual analogue scale (VAS). Patients used this cap for 25 min in each
application. They recorded their VAS score just after the therapy and 25 min, 1 h, 2 h and 3 h later. Two
patients could not use this therapy due to side effects (one due to cold intolerance and one due to vertigo)
in both applications. Therefore, therapeutic efficacy was evaluated in 26 patients. Twenty-five minutes
after treatment of the first attack, VAS score was decreased from 7.89 ± 1.93 to 5.54 ± 2.96 (P < 0.01).
Twenty-five minutes after treatment of the second attack, VAS score was decreased from 7.7 ± 1.8 to 5.4
± 3.55 (P < 0.01). Cold application alone may be effective in some patients suffering from migraine
attacks. Its combination with conventional drugs should be investigated in future studies.
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Introduction
Migraine headache is generally treated by anti-migraine
agents, analgesics and anti-emetic agents. Various non-
pharmacological methods including massage, trigger point
therapy, reflexology, spinal manipulation, therapeutic heat or
cold and exercise therapy have also been investigated in the
past for migraine patients (1–3). There are some reports which
support the efficacy of acupuncture in the treatment of
pediatric pain, including migraine (4). Ancient Greek and
Egyptian writings show that physicians of that time were
concerned about this disease and bloodletting and craniotomy
was used in some patients with headache (2,5).
The first cold treatment was done for headache patients in
1849. James Arnott wrote a manuscript on cold therapy in
which he used a mixture of salt and ice in patients to treat
headache (6). In another study, the efficacy of extra-cranial
pressure in combination with cold to treat headaches was
supported. They showed that simultaneous pressure of heat
and cold reduced the headache’s duration (7). Today, some
patients report that they treat their headache using physical
therapies, including cold application (5,8–10). Self-
administered pain relief manoeuvres have been investigated
in primary headache patients. They reported that application of
cold was the most-used manoeuvre in migraine without aura
(8). In a small study, Friedman et al. (11) reported the efficacy
of a non-invasive technique, intra-oral chilling, for acute
migraine headache pain when compared with oral sumatriptan
or placebo. Lance (12) reported the results of a new device,
which employs cold, pressure and heat around the head.
Fifteen out of twenty migraine patients and six out of seven
tension headache patients experienced some reduction in
headache severity. In another study, 9% of migraine patients
reported that a cold wrap was almost completely effective,
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However, they did not use an objective method to evaluate
headache severity (6). As a result, cold therapy is still not used
clinically for migraine patients as an alternative or additive
modality. In this study, we investigated the utility of cold
therapy for migraine attacks.
Materials and Methods
All patients in this study were admitted to the Ministry of
Health, Ankara Training and Research Hospital Headache
Center. Informed consent was obtained from all patients. We
obtained an Ethic Committee approval to conduct the study for
patients (between 14 and 60 years) who met the criteria
outlined below.
Inclusion Criteria
We proposed that all consecutively admitted patients, who met
the following criteria, participate in our study: (i) migraine
with aura and migraine without aura; (ii) chronic migraine
[migraine headache occurring for 15 or more days per month
for more than 3 months in the absence of medication overuse
and not attributed to another disorder (other type chronic
headache patients excluded)]; and that (iii) diagnosis was
made by International Headache Society (IHS) criteria (13).
The IHS determined new criteria for headache in 2004 (14),
but since our study had started before its publication, we used
the criteria reported in 1988 (13).
Exclusion Criteria
We excluded patients who had more than one type of headache
(menstrual migraine was also excluded), took prophylactic
treatment and patients with analgesic or ergotamine overuse.
We reasoned that menstrual migraine may have different
clinical characteristics and it can be more resistant than
non-menstrual migraine. Patients using prophylactic treatment
were deemed to be the possible cause of confusion when
evaluating the responses of migraine patients. Twenty-eight
migraine patients were included in this study. All patients were
evaluated by a neurologist.
Cap Administration
All patients kept a diary for two migraine attacks (before and
after the treatment). The diary included the time patients used
the gel cap, visual analogue scale (VAS) of patients (before the
treatment and 25 min, 1 h, 2 h, 3 h post-treatment), associated
symptoms (i.e. nausea and vomiting) and side effects.
Cold therapy was administered to the patients by gel cap
(Fig. 1) during both migraine attacks. The cap was stored in a
freezer. At the onset of the migraine attacks, patients wore the
cap and used it for 25 min. We choose 25 min as the time for
application of the gel cap based on the results of two published
studies (1,6). Headache severity was measured by VAS (0: no
pain to 10: severe pain) and pain relief was measured on a
similar scale. They recorded their headache severity before the
cap was placed and then 25 min, 1 h, 2 h and 3 h after the cap
therapy. Analgesic treatment was not taken within 25 min after
the onset of cold therapy. If patients did not experience
adequate relief from the headache, we allowed them to use
analgesics 25 min after the onset of cold therapy.
In this study, we did not evaluate the patients beyond 3 h.
This is a pilot study to determine the short-term effect of the
treatment.
Response Evaluation
An objective response was defined as a 50% or greater
reduction in pretreatment headache severity as measured by
VAS. Patients with VAS score (0) were evaluated as having a
complete response. A clinical benefit was defined as a
reduction in VAS by >25% in pretreatment headache severity.
We thought that a 25% decrease in VAS score is an important
level of clinical benefit. Therefore, we mentioned a 25%
reduction in VAS as a clinical benefit. A patient whose VAS
showed increase, no change or <25% decrease was defined as
no response.
Statistical Analysis
Bonferroni corrected Mann–Whitney U-test and Paired Sam-
ples t-test were used for statistical analysis. P-values <0.05
were accepted as significant.
Results
All patients were female and the median age was 29.25 ± 7.92
years (range: minimum 14; maximum 48). Twenty-six patients
had migraine without aura and two patients had migraine with
aura. The patients’ mean number of attacks per month was
3.11 ± 1.2 (minimum 1; maximum 5). Characteristics of
patients are shown in Table 1. Two patients could not use this
therapy due to side effects (one due to cold intolerance and one
due to vertigo) in both applications, leaving 26 patients to
evaluate.
Figure 1. The picture of cap used in the study.
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In the first application, 13 patients (50%) reported a clinical
benefit 25 min after the cold therapy. Objective response was
observed in 10 (38.4%) patients including three (11.5%)
patients who had a complete response. However, the other half
did not respond and needed to use analgesics 25 min after cold
therapy. Mean VAS scores of patients decreased from 7.89 ±
1.93 to 5.54 ± 2.96 in 25 min, 4.62 ± 3.16 in 1 h, 3.92 ± 3.32 in
2 h and 3.42 ± 3.55 in 3 h after cold therapy in first attack. VAS
scores at the twenty-fifth minute, first hour, second hour and
third hour of treatment were found to be significantly lower
compared to VAS scores before treatment (P < 0.01) (Fig. 2).
In patients with a clinical benefit, the mean number of attacks
was 3.30 ± 1.37, the mean pretherapy VAS score was 8.00 ±
2.04 and the duration of migraine attack was 21.23 ± 6.75 h. In
patients who did not have any clinical benefit, mean attack
number was 3.07 ± 1.03, mean VAS score before the therapy
was 7.69 ± 2.01 and duration of migraine attack was 19.00 ±
7.95 h. These were not significantly different between patients
with or without clinical benefit (P > 0.05).
Benefit Increased with Second Application
In the second application, 15 (57.6%) patients reported a
clinical benefit 25 min after the cold therapy. Objective
response was observed in 9 (34.6%) patients including
2 (7.7%) patients who had a complete response, but
11 (42.4%) did not respond and used analgesics. Mean VAS
scores decreased from 7.74 ± 1.81 to 5.40 ± 3.10 in 25 min,
4.76 ± 3.88 in 1 h, 4.60 ± 3.75 in 2 h and 4.04 ± 3.54 in 3 h.
VAS scores at the twenty-fifth minute, first hour, second hour
and third hour of treatment were found to be significantly
lower compared to VAS scores before the treatment (P < 0.01)
(Fig. 2).
Among 13 patients who responded to cold therapy in the first
attack, 10 of them (76.9%) also responded during their second
attack. Similarly, among 15 patients who did not respond in the
first attack, 9 (60%) did not have any response in the second
attack.
Median Analgesic Intake Time Increased
with the Second Application
Median analgesic intake time after onset of cold therapy was
45.0 ± 35.7 min (range: 25–120 min) in the first application
and 81.36 ± 118.4 (range: 25–420 min) min in the second.
Figure 3 shows the changes in VAS scores before and after the
treatment in patients with and without analgesic use. Three
patients reported a side effect during the two applications. Two
patients had cold intolerance and one had vertigo. One patient
with cold intolerance and another with vertigo did not continue
the therapy.
Discussion
Migraine is a chronic disease characterized by frequent
attacks, high levels of pain and disability during attacks,
Table 1. Characteristics of patients
Patients n Gender Mean age
(SD)
Frequency of
attacks
Disease duration
(year)
Attack duration*
(hour)
Initial VAS
scores
Female (%) Male (%)
Response (þ)* 13 13 (100) 0(0) 28.0 ± 7.8 3.30 ± 1.37 4.38 ± 4.42 21.23 ± 6.75 8.00 ± 2.04
Response ( )* 13 13 (100) 0(0) 31.0 ± 8.9 3.07 ± 1.03 5.46 ± 5.66 19.00 ± 7.95 7.69 ± 2.01
Total 28 28 (100) 0(0) 29.25 ± 7.9 3.11 ± 1.24 78 ± 4.84 20.39 ± 7.11 8.89 ± 0.91
P > 0.05.
*Response among 26 patients in 25 min of the first attack (two patients excluded from the response evaluation because of side effects).
Figure 2. VAS scores before and after the treatment of two attacks. Figure 3. VAS scores before and after the treatment in patients with and
without analgesic use.
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widespread disorder in the world, affecting  10–15% of
general population (19). There are four types of therapeutic
choice for migraine patients as follows: general measures,
abortive therapy, pain relief measures and prophylactic
therapy (20). Abortive therapy is commonly employed to
eliminate head pain and other symptoms associated with acute
migraine headache (1). A variety of drugs are known to be
effective in the treatment of migraine. Their side effects,
however, may restrict their use in some patients and the
medications used in these patients may worsen the present
headache or even create a new kind of headache known as a
drug abuse headache. It is well known that evidence-based
complementary and alternative medical therapies have shown
remarkable success in healing acute as well as chronic diseases
(21,22). Therefore, non-pharmacological methods are worthy
of investigation.
Various non-pharmacological methods have been investi-
gated in the past to control the pain of acute migraine attacks.
Application of an ice pack is a frequently used procedure
(1,5,8,20,23). However, there are only a few reported studies
in the literature regarding this non-pharmacological therapy
(1–3,5–7). Since the potential benefits of cold application in
headache patients have not yet been clearly understood, we
decided to investigate the benefits of cold application on
migraine patients.
Lance (12) reported the results of a new device which
employs cold, pressure and heat around the head. They showed
that headache severity was reduced in 15 out of 20 migraine
patients, and in 6 out of 7 tension headache patients. Diamond
and Freitag (5) found that a cold pack was effective in 71% of
headache patients, 80% of which were migraine headaches. In
a study reported by Robbins (6), 9% of migraine patients
reported the cold wrap as almost completely effective, 26.5%
as moderately effective and 29.0% as mildly effective.
However, they did not use an objective method to evaluate
headache severity. As a result, these are small studies and the
methods used are not practical for routine practice. New
studies are still needed to show the exact role of cold therapy
for migraine attacks.
In our study, migraine attacks were treated in  50% of the
patients by cold therapy alone, with significantly decreased
VAS scores after the therapy. In addition, we found that the
benefit of cold therapy continued progressively over time.
VAS scores gradually decreased after the therapy. This shows
that the benefits of cold therapy continued after the onset of
therapy. Moreover, there was consistency in the cold applica-
tions. Seventy-six percent of patients who had a response in
their first attack benefited from the cold therapy in the second
attack. Similarly, 60% of the patients who did not respond in
the first attack had no response in the second attack, either.
This study is not a randomized study and there is no control
group comparing usual therapeutic approaches such as
anti-migraine agents and anti-emetics. Therefore, we cannot
conclude that cold therapy is definitely effective in migraine
attack and we cannot suggest an evidence-based use of cold
therapy in migraine patients. We can say, however, that cold
therapy alone warrants investigation in future randomized
control studies.
In pharmacological trials on migraine drugs, rescue medi-
cations are usually allowed after 2 h. In our study, we allowed
our patients to take analgesics 25 min after the therapy onset.
However, median analgesics intake time after onset of cold
therapy was 45.0 min in the first and 81.36 min in the second
attack of patients who did not respond to gel cap therapy.
In the present study, 13 patients in first application and 11 in
second application used analgesic drugs due to inefficacy of
cold therapy alone. As seen in Fig. 3, the patients who did not
respond adequately to analgesic therapy also had lower VAS
scores. Therefore, we think that this patient group is a
refractory subgroup. However, we do not know whether
earlier treatment of these patients with analgesic therapy
would cause better responses.
The placebo effect in the pharmacological treatment of
migraine attacks may influence evaluation of the studies. In a
meta-analysis of 31 trials involving acute migraine patients, it
has been reported that the mean proportion of subjects who
experienced a treatment response to placebo was 28% (24). In
our study, the response rate was 50% in the first attack and
57% in the second attack. Moreover, placebo effect may vary
in each patient and each attack. Therefore, our results cannot
be completely attributed to placebo effect of gel therapy.
However, we cannot ignore its possible effect on our results.
If we accept the cold treatment as an effective modality in
migraine patients, there is still one more question to be
resolved: How does cold affect the migraine headache? Local
anesthesia is important in the use of cryotherapy. Lowering
pain stimuli may be caused by a decrease in contraction. The
gate theory suggests that the cold sensations overwhelm and
block transmission of the pain stimuli into the cerebral cortex.
Ice reduces the release of some substances including
histamines, vasoactive substances and enzymes that stimulate
nerve endings (6). However, the exact mechanism of
cryotherapy is still unclear.
In Vijayan’s (1) study, two patients could not apply adequate
pressure in cold therapy because of tenderness. In our study
three patients showed side effects in both applications. Two
patients had cold intolerance and one had vertigo. Two of them
discontinued the therapy. The use of gel packs is a safe method
of applying cold in adjunct treatment of acute headache.
Conclusion
Cold application alone may be effective in some patients
suffering from migraine attacks. This study is not a random-
ized study and there is no control group comparing usual
therapeutic approaches such as anti-migraine agents and
anti-emetics. However, randomized studies are needed to
clarify the efficacy of cold therapy alone in these patients. Its
use in combination with well-known therapeutic tools such as
anti-migraine agents, analgesics and anti-emetic agents should
be investigated in further studies.
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